Free
Critical Care Medicine  |   May 2011
Toll-Like Receptor 4 Inhibitor TAK-242 Attenuates Acute Kidney Injury in Endotoxemic Sheep
Author Affiliations & Notes
  • Johan Fenhammar, M.D.
    *
  • Mats Rundgren, M.D., Ph.D.
  • Jakob Forestier, M.D.
  • Sigridur Kalman, M.D., Ph.D.
    §
  • Stefan Eriksson, O.D., Ph.D.
  • Robert Frithiof, M.D., Ph.D.
    #
  • * PhD Student, Resident Physician, Department of Anaesthesia and Intensive Care, Karolinska University Hospital, and Department of Clinical Science Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; † Associate Professor, Department of Physiology and Pharmacology, Karolinska Institutet; ‡ Resident Physician, Department of Anaesthesia and Intensive Care, Karolinska University Hospital, and Department of Clinical Science Intervention and Technology, Karolinska Institutet; § Associate Professor, Department of Anaesthesia and Intensive Care, Karolinska University Hospital, and Department of Clinical Science Intervention and Technology, Karolinska Institutet; ∥ Associate Professor, Chairman, Department of Physiology and Pharmacology, Karolinska Institutet; # Primary Investigator, Department of Physiology and Pharmacology, Karolinska Institutet.
Article Information
Critical Care Medicine / Cardiovascular Anesthesia / Critical Care / Infectious Disease / Renal and Urinary Systems / Electrolyte Balance
Critical Care Medicine   |   May 2011
Toll-Like Receptor 4 Inhibitor TAK-242 Attenuates Acute Kidney Injury in Endotoxemic Sheep
Anesthesiology 5 2011, Vol.114, 1130-1137. doi:10.1097/ALN.0b013e31820b8b44
Anesthesiology 5 2011, Vol.114, 1130-1137. doi:10.1097/ALN.0b013e31820b8b44
What We Already Know about This Topic:
  • Acute kidney injury contributes to mortality in patients with sepsis.

  • Lipopolysaccharide from Gram-negative bacterial cell walls may cause kidney injury by binding to toll-like receptor 4 in the kidney.

What This Article Tells Us That Is New:
  • In this sheep model, a toll-like receptor antagonist decreased hypotension and improved renal function during lipopolysaccharide infusion.

THE recent discovery of the toll-like receptors (TLRs) has furthered the understanding of the signaling pathways for pathogen recognition and immune activation in sepsis, in particular when Gram-negative bacteria are the origin.1,2 One of these receptors, TLR4, is expressed on different immune cells and in different organs, including the kidney.3,4 Lipopolysaccharide, a component of the cell wall of Gram-negative bacteria and a main ligand for TLR4, may play a significant role in the development of sepsis. TLR4 mediates the actions of lipopolysaccharide through production and release of cytokines and stimulation of inflammatory cells.5–7 Recent studies in mice have demonstrated that anti-TLR4 antibodies reduce mortality in endotoxemia8 and in experimental polymicrobial sepsis.9 
Sepsis is a common cause of acute kidney injury (AKI) in critically ill patients; despite advanced treatment, mortality remains high.10,11 The exact cause of septic AKI is unknown. However, recent data suggest that interaction between Gram-negative bacteria and both systemic and renal-bound TLR4 may contribute to septic AKI.12 The presence of TLR4 has been displayed in both human and murine renal tissue,13,14 and sepsis increases the expression of TLR4 in renal vascular and epithelial cells in both the Bowman capsule and the tubulus.3,15 Circulating endotoxin reaches these renal sites.3,16 Furthermore, activation of extrarenal TLR4 results in the stimulation of proinflammatory cytokines that may harm the kidney by inducing the release of reactive oxygen species and neutrophil granule proteins.17 These data provide a theoretic basis for TLR4-induced AKI, but studies investigating the impact of TLR4 activation on renal function during endotoxemia or sepsis are lacking. During endotoxemia, C3H/HeJ mice with a mutation causing a dysfunctional TLR4 showed an attenuated blood urea nitrogen increase compared with controls,18 indirectly suggesting better kidney function. However, to our knowledge, the effects on urine output, creatinine clearance, or central hemodynamics caused by TLR4 during sepsis or endotoxemia have never been evaluated. Recently available selective pharmacologic antagonists for the TLR4 suitable for iv administration have made it possible to explore further the importance of TLR4 in sepsis and endotoxemia in a large animal model mimicking the clinical scenario and facilitating extensive cardiovascular monitoring with repeated blood and urine sampling. This study was conducted to investigate the role of TLR4 in mediating AKI in endotoxemic sheep. Conscious animals were pretreated with the selective TLR4 inhibitor TAK-242 or vehicle and subjected to 24 h of endotoxemia, during which renal function was monitored. To explore if any effect of TAK-242 was because of the prevention of hypotension, a third group of lipopolysaccharide-treated animals receiving norepinephrine titrated to maintain baseline blood pressure was added.
Materials and Methods
The study protocol was approved in advance by the Regional Ethics Committee for Experiments in Animals, Stockholm, Sweden. The experiments were conducted in accordance with The European Convention for Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes (Council of Europe No. 123, Strasbourg, France, 1985).
Animals and Surgical Preparation
Twenty adult Texel crossbred ewes, weighing a mean ± SEM of 58 ± 3 kg, were used. They had free access to water and were housed individually in pens. Two times per day, they were fed hay and 75-g commercial pellets with the addition of 6-g NaCl. Before the experiments, one carotid artery was surgically exteriorized and placed in a cervical skin loop, as previously described.19 
Experimental Preparation
The experiments were performed with conscious animals placed in individual pens with access to water and hay. Intravascular catheterizations were performed under local anesthesia (lidocaine hydrochloride, 5 mg/ml) at least 4 h before starting the experiments. The exteriorized carotid artery was cannulated and used for measurement of arterial blood pressure and arterial blood sampling. Venous blood sampling was performed via  a catheter placed in the left jugular vein. A balloon-tipped pulmonary artery catheter (7.5F Swan-Ganz; Edwards Lifesciences, Irvine, CA) was inserted into the pulmonary artery via  an introducer in the right jugular vein. The position in the pulmonary artery was determined by pressure guidance on a monitor. The iv infusions were performed in a catheter placed in the right jugular vein. A retention catheter (14F) was inserted into the bladder via  the urethra and used for urine collection.
Hemodynamic Recordings
Hemodynamic measurements were acquired online with a sampling rate of 50 Hz via  a multichannel interface (MP150; Biopac Systems, Goleta, CA) with acquisition software (AcqKnowledge 3.8.1.; Biopac Systems) and stored on a computer. The different blood pressures were measured via  pressure transducers (DPT-6003; PVB Medizin Technik, BMBH, Kirchseen, Germany). The pressure transducers were calibrated to atmospheric pressure at the level of the heart and to 100 or 25 mmHg using a saline column. The pulmonary artery catheter was connected to a monitoring system (Vigilance Monitor; Edwards Lifesciences), cardiac output was calculated every 30–60 s, and core temperature was measured continuously. When the body temperature exceeded the upper range for automatic measurements (i.e.  , 41°C), manual cardiac output measurements were performed by three consecutive injections (10 ml) of isotonic saline. Mean arterial pressure (MAP) and mean pulmonary arterial pressure were calculated and displayed online.
Blood, Plasma, and Urine Analyses
The venous blood was portioned into prechilled tubes with heparin or EDTA as anticoagulant and immediately centrifuged at 4°C (3000 rpm) for 10 min. Plasma aliquots were stored at −20°C until assayed for creatinine (Jaffe method) and blood urea nitrogen (Synchron LX; Beckman Instruments, Richmond, CA). Other portions of plasma were taken for determination of hematocrit and protein concentration by refractometry (Atago Co, Tokyo, Japan). The carotid blood samples were used for immediate arterial blood gas analyses (ABL 77; Radiometer, Copenhagen, Denmark). In addition, lactate (Accu-trend Lactate; Roche Diagnostics, Basel, Switzerland) was analyzed using arterial blood. Urinary concentrations of N  -acetyl-β-d-glucosaminidase (U-NAG) were measured by a colorimetric assay (Cobas Mira; Hoffmann-La Roche AG, Basel, Switzerland) in groups receiving TAK-242 or vehicle.
Experimental Protocol
Sheep were randomized to receive a bolus dose (2 mg/kg), followed by a continuous infusion (4 mg · kg−1· 24 h−1) of either the selective TLR4 inhibitor, TAK-242 (10 mg/ml) (n = 7), or vehicle (n = 7) (0.6 ml · kg−1· 24 h−1). Randomization was blinded and performed with random alphabetic letters assigned to each animal. The treatment remained blinded for the investigators until after the experiments were finished. Endotoxemia was started after the bolus dose was given by iv infusion of Escherichia coli  lipopolysaccharide (serotype 0111:B4; 600,000 endotoxin units ·μg; Sigma-Aldrich Sweden AB, Stockholm, Sweden). The infusion rate was slowly increased during the first 30 min to reach 3 μg · kg−1· h−1. This rate was then maintained for the remainder of the experiment (24 h). In an additional group, lipopolysaccharide was administered as described; however, to prevent hypotension, norepinephrine (200 μg/ml) was titrated to maintain MAP at baseline levels. In all groups, baseline values were collected 60 min before the start of lipopolysaccharide infusion. Fluid volume support was administered as Ringer's acetate solution (B. Braun Melsungen, AG, Melsungen, Germany) iv at 0.5 ml · kg−1· h−1. In the norepinephrine group, additional volume support was given as bolus doses (200–250 ml) of hydroxyethyl starch (130/0.4) if MAP did not increase as expected in response to norepinephrine. Blood samples (approximately 20-ml venous blood and 1-ml arterial blood) were drawn at baseline and at 6, 12, 18, and 24 h after commencement of endotoxemia. Urinary output was measured, and urine samples were collected every second hour.
The occurrence of AKI was determined by reduced renal function, measured as decreased urine output and creatinine clearance.20 
Statistical Analysis
Cardiovascular parameters were averaged off-line. Cardiac output was indexed to body surface area (0.09 × body weight0.67). Creatinine clearance was calculated as follows: (Urine Flow) × (Urine Creatinine Concentration)/Plasma Creatinine Concentration.
All statistical calculations were performed using computer software (Statistica 8.0; Statsoft Inc., Tulsa, OK), and the graphs were created with a computer program (ς Plot 11.0; SPSS Inc., Chicago, IL). Data are expressed as mean ± SEM. Urine production values were transformed to follow a normal distribution by taking the logarithm of the raw data. Changes in parameters over time were analyzed according to a two-way repeated-measures ANOVA, which included the time points of 0, 12, and 24 h after the start of lipopolysaccharide infusion as within effects and treatment (control, TAK-242, or norepinephrine) as a between effect. In case of a significant group or interaction effect, group differences were analyzed by a one-way ANOVA and a Tukey test at each time point included in the initial ANOVA. Furthermore, a one-way repeated-measures ANOVA was performed for each treatment to investigate if that group changed significantly over time. The result of this analysis is not displayed in the figures and is only referred to in the Results section. The significance level was set at P  ≤ 0.05.
Results
Endotoxemia resulted in a hyperdynamic response, with a decrease in MAP and an increase in cardiac index and tachycardia (fig. 1, A–C; P  < 0.05). TAK-242 attenuated the change in MAP and heart rate (fig. 1, A and C, respectively) but had no significant effect on cardiac index (fig. 1B). Body temperature increased and remained higher than baseline values throughout the experiment (fig. 1D, P  < 0.001). TAK-242 had no significant effect on the fever response (P  = 0.8). At the end of the experiment, animals in the TAK-242 group showed normal behavior, with adequate intake of hay and water. The sheep in the vehicle group had a significantly more affected general state of health and were often lying down, without eating or drinking.
Fig. 1.  Changes in mean arterial blood pressure (A  ), cardiac index (B  ), heart rate (C  ), and body temperature (D  ) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure (MAP) at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P  ≤ 0.05. *, a significant difference between TAK-242 and vehicle; and †, a significant difference between vehicle and NE.
Fig. 1. 
	Changes in mean arterial blood pressure (A 
	), cardiac index (B 
	), heart rate (C 
	), and body temperature (D 
	) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure (MAP) at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P 
	≤ 0.05. *, a significant difference between TAK-242 and vehicle; and †, a significant difference between vehicle and NE.
Fig. 1.  Changes in mean arterial blood pressure (A  ), cardiac index (B  ), heart rate (C  ), and body temperature (D  ) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure (MAP) at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P  ≤ 0.05. *, a significant difference between TAK-242 and vehicle; and †, a significant difference between vehicle and NE.
×
After an early peak, urine output decreased significantly as a result of the lipopolysaccharide infusion (P  < 0.001, fig. 2A). However, TAK-242 abolished the reduction in diuresis (fig. 2A). This was also reflected in the creatinine clearance: TAK-242 prevented the reduction seen in the vehicle-treated animals (fig. 2B). Furthermore, the reduced renal function caused by endotoxemia caused a significant increase in plasma creatinine and blood urea nitrogen concentrations (P  < 0.001 for both; fig. 2, C and D, respectively). These effects were abolished by pretreatment with TAK-242 (fig. 2, C and D, respectively). Moreover, TAK-242 reduced the hyperlactemia produced by the lipopolysaccharide infusion (fig. 2E). As an estimate of tubular cell injury, the urinary NAG concentration was analyzed. In the vehicle group, U-NAG remained close to baseline levels during the initial 12 hours of endotoxemia; thereafter, it increased significantly (P  < 0.001, fig. 2F). TAK-242 abolished the increase in U-NAG (fig. 2F).
Fig. 2.  Changes in urine output (A  ), creatinine clearance (B  ), plasma (P) creatinine (C  ), blood urea nitrogen (BUN) (D  ), P-lactate (E  ), and urinary N  -acetyl-β-d-glucosaminidase (U-NAG) (F  ) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P  ≤ 0.05. * indicates a significant difference between TAK-242 and vehicle; and #,  a significant difference between TAK-242 and NE.
Fig. 2. 
	Changes in urine output (A 
	), creatinine clearance (B 
	), plasma (P) creatinine (C 
	), blood urea nitrogen (BUN) (D 
	), P-lactate (E 
	), and urinary N 
	-acetyl-β-d-glucosaminidase (U-NAG) (F 
	) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P 
	≤ 0.05. * indicates a significant difference between TAK-242 and vehicle; and #, 
	a significant difference between TAK-242 and NE.
Fig. 2.  Changes in urine output (A  ), creatinine clearance (B  ), plasma (P) creatinine (C  ), blood urea nitrogen (BUN) (D  ), P-lactate (E  ), and urinary N  -acetyl-β-d-glucosaminidase (U-NAG) (F  ) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P  ≤ 0.05. * indicates a significant difference between TAK-242 and vehicle; and #,  a significant difference between TAK-242 and NE.
×
Systemic vascular resistance decreased and mixed venous oxygen saturation increased as a result of the lipopolysaccharide infusion, without intergroup differences (P  < 0.001, table 1). The mean pulmonary artery pressure increased progressively during the experiment in the vehicle-treated animals (P  < 0.001, table 1), but this increase was significantly attenuated by TAK-242 (table 1). Furthermore, TAK-242 prevented the decrease in Po2seen in the vehicle-treated animals (table 1). The arterial partial pressure of carbon dioxide, base excess, pH, plasma protein, and hematocrit were not significantly changed by either endotoxemia or treatment (table 1). However, for an unknown reason, the norepinephrine-treated sheep had a significantly lower pH at baseline.
Table 1.  Systemic Variables
Image not available
Table 1.  Systemic Variables
×
To explore the possibility that the effects of TAK-242 on renal function were because of the prevention of hypotension, a third group of animals receiving lipopolysaccharide and norepinephrine was added. In this group, hypotension was abolished (fig. 1A); and cardiac index, heart rate, and temperature were not significantly different from the other groups (fig. 1, B–D, respectively). However, AKI still developed as indicated by a reduction in urine output and creatinine clearance (P  = 0.002 and P  < 0.001, respectively; fig. 2, A and B, respectively) and an increase in plasma creatinine and blood urea nitrogen (P  < 0.001 for both; fig. 2, C and D, respectively). Plasma lactate increased more in response to lipopolysaccharide compared with TAK-242 (fig. 2E) and was significantly increased over time (P  = 0.002). The norepinephrine infusion was started after 7.3 ± 0.4 h, and the amount infused was 229 ± 83 μg/kg. The volume of infused hydroxyethyl starch was 20 ± 5 ml/kg.
Discussion
This study was conducted to investigate the role of TLR4 in mediating AKI in endotoxemic sheep. The main finding was that pretreatment with a TLR4 inhibitor reduced the renal dysfunction caused by lipopolysaccharide infusion. The effect was significantly greater compared with treatment with norepinephrine in a dose that prevented hypotension. Furthermore, systemic TLR4 inhibition abolished the lipopolysaccharide-induced elevation in urinary NAG, indicating a possible reduction of renal tubular damage.
Previous studies8,9,18,21–23 performed in rodents have not reported effects on blood pressure or cardiac output by TLR4 antibodies or TLR4 knockout during endotoxemia or sepsis. Herein, the continuous infusion of lipopolysaccharide resulted in hyperdynamic circulation, characterized by increasing cardiac output, hypotension, tachycardia, and reduced systemic vascular resistance. Anesthesia has the potential to severely affect cardiovascular performance24 and reduce renal function during endotoxemia25 but because these animals remained conscious throughout the experiment, there was no influence from any anesthetic agent on the results.
In the vehicle-treated animals, MAP reached concentrations that usually are considered to be less than the lower limit for renal blood flow autoregulation. In theory, this would cause a reduction in renal blood flow that could contribute to the decreased creatinine clearance and urine output. However, previous studies26,27 in conscious sheep have shown that renal blood flow actually increases during sepsis and endotoxemia. Although renal blood flow was not measured herein, the cardiovascular reaction to lipopolysaccharide, including increased cardiac output, tachycardia, and hypotension, is identical to that in previous studies.26–28 This indicates that the effect of TAK-242 in the current study is not because of prevention of prerenal azotemia caused by blood flow restriction. The attenuated decrease in MAP by TLR4 inhibition could still have had a positive effect on glomerular perfusion pressure, facilitating higher creatinine clearance and diuresis in the TAK-242 group. This may, in part, explain the findings in this study and previous investigations8,18,22,23 performed in rodents (in which effects on blood pressure were not reported), showing a role for TLR4 in mediating septic AKI. To explore further this question, we added a group of sheep subjected to endotoxemia treated with norepinephrine. The results show that these sheep still develop AKI, although MAP was the same as in the TAK-242 group, indicating that hypotension is of limited importance for renal dysfunction in this model of endotoxemia. Changes in renal blood flow by norepinephrine may have resulted in kidney ischemia, although blood pressure remained at baseline levels. However, norepinephrine causes no significant reduction in an already increased renal blood flow or change in renal microcirculation in septic hypotensive sheep.29 This and the results presented herein indicate that norepinephrine had only a minor effect on central and renal hemodynamics, in addition to maintaining MAP. Thus, the renal-protective effect of TLR4 inhibition does not depend on prevention of hypotension. Further studies are needed to clarify the exact mechanisms of action, but results30 from studies on renal ischemia/reperfusion injury suggest that TAK-242 may act directly on renal parenchyma.
Renal tubular dysfunction may be a contributing factor to lipopolysaccharide-induced AKI in our model. U-NAG is a glycosidase found in proximal tubular epithelial cell lysosomes, and an increase in urinary levels is commonly used as a marker of tubular damage.31 Interestingly, Good et al.  32 have suggested a TLR4-dependent mechanism in which lipopolysaccharide inhibits H+secretion and HCO3absorption; this mechanism inhibits the renal correction of lipopolysaccharide-induced systemic acidosis, contributing further to tubular dysfunction. The drastic increase of U-NAG in the vehicle-treated animals may suggest a tubular injury. However, because creatinine clearance and urine production decreased before the increase in U-NAG, we believe that tubular damage is probably not the main cause of AKI in this model.
Lipopolysaccharide acts as the primary ligand for TLR4 and activates an intracellular signaling cascade that involves both myeloid differentiation primary response gene 88 (MyD88)-dependent and MyD88-independent pathways. This results in up-regulation of nuclear factor κB and subsequent induced expression of genes encoding for inflammatory mediators, such as tumor necrosis factor α and interleukin 6.33 The pharmacologic substance used for inhibition of TLR4 in the current study, TAK-242, binds directly to the amino acid Cys747 in the intracellular domain of the receptor,34 thus inhibiting the activation of the downstream signaling pathway by lipopolysaccharide. Experiments to confirm the specificity of TAK-242 for TLR4 have mainly been performed in rodents and humans. However, sheep TLR4 corresponds well to human TLR4,35 and TAK-242 abolished the cardiovascular effects of TLR4 activation in sheep. This makes us confident that the effects of TAK-242 on renal function were because of TLR4 inhibition. Although we did not measure cytokines, we believe that reduced production of these inflammatory mediators may be a large contributing mechanism for the results obtained in the current study. This idea is supported by findings from Cunningham et al.  18 in a 6-h model of endotoxemia in C3H/HeJ mice with loss of function in TLR4. Their results indicate that TLR4-mediated renal injury depends on induction of tumor necrosis factor α production and renal neutrophil infiltration within the kidney.18 On the other hand, C3H/HeJ mice, lacking functional TLR4, subjected to polymicrobial infections still develop sepsis,22,23 suggesting that TLR4 activation by lipopolysaccharide may not be the sole mechanism in septic AKI. TLR4 inhibition significantly attenuated the increase in mean pulmonary artery pressure, prevented the decrease in Po2, and reduced lactate production by endotoxemia. These results are probably a reflection of attenuated cytokine production because reduced cytokine levels in the lung have been reported in TLR4-deficient mice36 and after TAK-242 treatment in endotoxemic mice.37 
In contrast to findings from previous studies reporting that activation of TLR4 by lipopolysaccharide causes changes in body temperature, TAK-242 did not reduce fever in the current study. In mice, TAK-242 reduced lipopolysaccharide-induced hypothermia21; and C3H/HeJ mice showed an absent temperature reaction after lipopolysaccharide challenge.38 TLR4-dependent production of prostaglandin E2 in macrophages has been proposed as a mechanism for this lipopolysaccharide-induced fever,39 but this theory has not been confirmed in sheep. Therefore, the current results could be because of incomplete inhibition of TLR4 or because other fever-inducing mechanisms (vs.  those that are TLR4 dependent) are important in conscious endotoxemic sheep. Another likely explanation is that the lipopolysaccharide infused was not perfectly pure and contained pyrogens activating receptors other than TLR4.
There are some limitations to this study that we would like to acknowledge. TLR4 inhibition was administered before endotoxemia and the subsequent development of AKI. Therefore, this study did not elucidate whether TLR4 inhibition may improve renal function when renal injury is already present. However, these data may still be of potential interest for clinical practice because prophylactic treatment with a TLR4 inhibitor may prove useful before certain invasive and surgical procedures. For instance, during major abdominal surgery, there is a risk for infection with Gram-negative bacteria and subsequent sepsis,40 for which antibiotics are usually administered perioperatively or preoperatively. Furthermore, the renal-protective benefit of pretreatment with TLR4 inhibitors may include disorders other than sepsis because TLR4 can be activated by lipopolysaccharide and as a response to tissue damage.41,42 Another limitation is that these experiments were performed with an observation period of 24 h and may, therefore, be too short to represent the common clinical manifestations of sepsis. Moreover, to our knowledge, this is the first study investigating the effect on renal function during sepsis after TLR4 inhibition; at present, these findings are limited to this certain experimental setting and need to be confirmed by others before any interpretation to clinical practice can be performed. A recent clinical trial43 investigating the effects of TAK-242 on human sepsis was terminated because TAK-242 failed to decrease serum interleukin 6 levels. The treatment was well tolerated but did not significantly improve survival. Because the enrollment of patients was discontinued prematurely, definite conclusions about the survival efficacy of TAK-242 in humans are still lacking. Direct comparisons with the current study are difficult because only 40% of the patients had Gram-negative infections and there was no special emphasis on renal function. However, the result of the current study suggests that septic patients with AKI would be interesting to investigate in future clinical trials with TAK-242.
Based on the findings from the current study, we conclude that activation of TLR4 may mediate the development of endotoxemic AKI in conscious sheep. This effect is not only because of a reduction in blood pressure because renal function was not maintained merely by preventing hypotension in animals treated with norepinephrine. Further studies are needed to investigate the full mechanism of activated TLR4-induced AKI, if TLR4 inhibition can reverse an already present AKI and if blockade of TLR4 is efficient during renal dysfunction induced by bacterial infection.
The authors are grateful for the excellent laboratory assistance of Azar Baharpoor, M.Sc., Technician, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
References
Poltorak A, Smirnova I, He X, Liu MY, Van Huffel C, McNally O, Birdwell D, Alejos E, Silva M, Du X, Thompson P, Chan EK, Ledesma J, Roe B, Clifton S, Vogel SN, Beutler B: Genetic and physical mapping of the Lps locus: Identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 1998; 24:340–55Poltorak, A Smirnova, I He, X Liu, MY Van Huffel, C McNally, O Birdwell, D Alejos, E Silva, M Du, X Thompson, P Chan, EK Ledesma, J Roe, B Clifton, S Vogel, SN Beutler, B
Hashimoto C, Hudson KL, Anderson KV: The Toll gene of Drosophila  , required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988; 52:269–79Hashimoto, C Hudson, KL Anderson, KV
El Achkar TM, Huang X, Plotkin Z, Sandoval RM, Rhodes GJ, Dagher PC: Sepsis induces changes in the expression and distribution of Toll-like receptor 4 in the rat kidney. Am J Physiol Renal Physiol 2006; 290:F1034–43El Achkar, TM Huang, X Plotkin, Z Sandoval, RM Rhodes, GJ Dagher, PC
Zarember KA, Godowski PJ: Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168:554–61Zarember, KA Godowski, PJ
O'Neill LA, Bryant CE, Doyle SL: Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009; 61:177–97O'Neill, LA Bryant, CE Doyle, SL
El Achkar TM, Dagher PC: Renal Toll-like receptors: Recent advances and implications for disease. Nat Clin Pract Nephrol 2006; 2:568–81El Achkar, TM Dagher, PC
Leon CG, Tory R, Jia J, Sivak O, Wasan KM: Discovery and development of toll-like receptor 4 (TLR4) antagonists: A new paradigm for treating sepsis and other diseases. Pharm Res 2008; 25:1751–61Leon, CG Tory, R Jia, J Sivak, O Wasan, KM
Roger T, Froidevaux C, Le Roy D, Reymond MK, Chanson AL, Mauri D, Burns K, Riederer BM, Akira S, Calandra T: Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A 2009; 106:2348–52Roger, T Froidevaux, C Le Roy, D Reymond, MK Chanson, AL Mauri, D Burns, K Riederer, BM Akira, S Calandra, T
Daubeuf B, Mathison J, Spiller S, Hugues S, Herren S, Ferlin W, Kosco-Vilbois M, Wagner H, Kirschning CJ, Ulevitch R, Elson G: TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J Immunol 2007; 179:6107–14Daubeuf, B Mathison, J Spiller, S Hugues, S Herren, S Ferlin, W Kosco-Vilbois, M Wagner, H Kirschning, CJ Ulevitch, R Elson, G
Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294:813–8Uchino, S Kellum, JA Bellomo, R Doig, GS Morimatsu, H Morgera, S Schetz, M Tan, I Bouman, C Macedo, E Gibney, N Tolwani, A Ronco, C Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators,
Bagshaw SM, George C, Bellomo R: Early acute kidney injury and sepsis: A multicentre evaluation. Crit Care 2008; 12:R47Bagshaw, SM George, C Bellomo, R
El Achkar TM, Hosein M, Dagher PC: Pathways of renal injury in systemic gram-negative sepsis. Eur J Clin Invest 2008; 38(suppl 2):39–44El Achkar, TM Hosein, M Dagher, PC
Samuelsson P, Hang L, Wullt B, Irjala H, Svanborg C: Toll-like receptor 4 expression and cytokine responses in the human urinary tract mucosa. Infect Immun 2004; 72:3179–86Samuelsson, P Hang, L Wullt, B Irjala, H Svanborg, C
Medzhitov R, Preston-Hurlburt P, Janeway CA Jr: A human homologue of the Drosophila  Toll protein signals activation of adaptive immunity. Nature 1997; 388:394–7Medzhitov, R Preston-Hurlburt, P Janeway, CA
Zager RA, Johnson AC, Lund S: “Endotoxin tolerance”: TNF-alpha hyper-reactivity and tubular cytoresistance in a renal cholesterol loading state. Kidney Int 2007; 71:496–503Zager, RA Johnson, AC Lund, S
Kang YH, Falk MC, Bentley TB, Lee CH: Distribution and role of lipopolysaccharide in the pathogenesis of acute renal proximal tubule injury. Shock 1995; 4:441–9Kang, YH Falk, MC Bentley, TB Lee, CH
Linas SL, Whittenburg D, Repine JE: Role of neutrophil derived oxidants and elastase in lipopolysaccharide-mediated renal injury. Kidney Int 1991; 39:618–23Linas, SL Whittenburg, D Repine, JE
Cunningham PN, Wang Y, Guo R, He G, Quigg RJ: Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J Immunol 2004; 172:2629–35Cunningham, PN Wang, Y Guo, R He, G Quigg, RJ
Frithiof R, Eriksson S, Bayard F, Svensson T, Rundgren M: Intravenous hypertonic NaCl acts via  cerebral sodium-sensitive and angiotensinergic mechanisms to improve cardiac function in haemorrhaged conscious sheep. J Physiol 2007; 583:1129–43Frithiof, R Eriksson, S Bayard, F Svensson, T Rundgren, M
Kellum JA, Bellomo R, Ronco C: The concept of acute kidney injury and the RIFLE criteria. Contrib Nephrol 2007; 156:10–6Kellum, JA Bellomo, R Ronco, C
Sha T, Sunamoto M, Kitazaki T, Sato J, Ii M, Iizawa Y: Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model. Eur J Pharmacol 2007; 571:231–9Sha, T Sunamoto, M Kitazaki, T Sato, J Ii, M Iizawa, Y
Feterowski C, Emmanuilidis K, Miethke T, Gerauer K, Rump M, Ulm K, Holzmann B, Weighardt H: Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 2003; 109:426–31Feterowski, C Emmanuilidis, K Miethke, T Gerauer, K Rump, M Ulm, K Holzmann, B Weighardt, H
Dear JW, Yasuda H, Hu X, Hieny S, Yuen PS, Hewitt SM, Sher A, Star RA: Sepsis-induced organ failure is mediated by different pathways in the kidney and liver: Acute renal failure is dependent on MyD88 but not renal cell apoptosis. Kidney Int 2006; 69:832–6Dear, JW Yasuda, H Hu, X Hieny, S Yuen, PS Hewitt, SM Sher, A Star, RA
Soehnlein O, Eriksson S, Hjelmqvist H, Andersson A, Mörgelin M, Lindbom L, Rundgren M, Frithiof R: Anesthesia aggravates lung damage and precipitates hypotension in endotoxemic sheep. Shock 2010; 34:412–9Soehnlein, O Eriksson, S Hjelmqvist, H Andersson, A Mörgelin, M Lindbom, L Rundgren, M Frithiof, R
Frithiof R, Soehnlein O, Eriksson S, Fenhammar J, Hjelmqvist H, Lindbom L, Rundgren M: The effects of isoflurane anesthesia and mechanical ventilation on renal function during endotoxemia [epub ahead of print]. Acta Anaesthesiol. Scand. 2011Frithiof, R Soehnlein, O Eriksson, S Fenhammar, J Hjelmqvist, H Lindbom, L Rundgren, M
Langenberg C, Wan L, Egi M, May CN, Bellomo R: Renal blood flow in experimental septic acute renal failure. Kidney Int 2006; 69:1996–2002Langenberg, C Wan, L Egi, M May, CN Bellomo, R
Schwieger IM, Schiffer ER, Morel DR: Effects of fenoldopam on systemic and splanchnic haemodynamics and oxygen delivery/consumption relationship during hyperdynamic ovine endotoxaemia. Intensive Care Med 1998; 24:509–18Schwieger, IM Schiffer, ER Morel, DR
Wan L, Langenberg C, Bellomo R, May CN: Angiotensin II in experimental hyperdynamic sepsis. Crit Care 2009; 13:R190Wan, L Langenberg, C Bellomo, R May, CN
Di Giantomasso D, Morimatsu H, May CN, Bellomo R: Intrarenal blood flow distribution in hyperdynamic septic shock: Effect of norepinephrine. Crit Care Med 2003; 31:2509–13Di Giantomasso, D Morimatsu, H May, CN Bellomo, R
Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander SI, Sharland AF, Chadban SJ: TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117:2847–59Wu, H Chen, G Wyburn, KR Yin, J Bertolino, P Eris, JM Alexander, SI Sharland, AF Chadban, SJ
Wellwood JM, Ellis BG, Price RG, Hammond K, Thompson AE, Jones NF: Urinary N-acetyl-beta-D-glucosaminidase activities in patients with renal disease. Br Med J 1975; 3:408–11Wellwood, JM Ellis, BG Price, RG Hammond, K Thompson, AE Jones, NF
Good DW, George T, Watts BA III: Lipopolysaccharide directly alters renal tubule transport through distinct TLR4-dependent pathways in basolateral and apical membranes. Am J Physiol Renal Physiol 2009; 297:F866–74Good, DW George, T Watts, BA
Akira S: Toll-like receptor signaling. J Biol Chem 2003; 278:38105–8Akira, S
Takashima K, Matsunaga N, Yoshimatsu M, Hazeki K, Kaisho T, Uekata M, Hazeki O, Akira S, Iizawa Y, Ii M: Analysis of binding site for the novel small-molecule TLR4 signal transduction inhibitor TAK-242 and its therapeutic effect on mouse sepsis model. Br J Pharmacol 2009; 157:1250–62Takashima, K Matsunaga, N Yoshimatsu, M Hazeki, K Kaisho, T Uekata, M Hazeki, O Akira, S Iizawa, Y Ii, M
Menzies M, Ingham A: Identification and expression of Toll-like receptors 1–10 in selected bovine and ovine tissues. Vet Immunol Immunopathol 2006; 109:23–30Menzies, M Ingham, A
Baumgarten G, Knuefermann P, Wrigge H, Putensen C, Stapel H, Fink K, Meyer R, Hoeft A, Grohe C: Role of Toll-like receptor 4 for the pathogenesis of acute lung injury in Gram-negative sepsis. Eur J Anaesthesiol 2006; 23:1041–8Baumgarten, G Knuefermann, P Wrigge, H Putensen, C Stapel, H Fink, K Meyer, R Hoeft, A Grohe, C
Seki H, Tasaka S, Fukunaga K, Shiraishi Y, Moriyama K, Miyamoto K, Nakano Y, Matsunaga N, Takashima K, Matsumoto T, Ii M, Ishizaka A, Takeda J: Effect of Toll-like receptor 4 inhibitor on LPS-induced lung injury. Inflamm Res 2010; 59:837–45Seki, H Tasaka, S Fukunaga, K Shiraishi, Y Moriyama, K Miyamoto, K Nakano, Y Matsunaga, N Takashima, K Matsumoto, T Ii, M Ishizaka, A Takeda, J
Steiner AA, Chakravarty S, Robbins JR, Dragic AS, Pan J, Herkenham M, Romanovsky AA: Thermoregulatory responses of rats to conventional preparations of lipopolysaccharide are caused by lipopolysaccharide per se  -not by lipoprotein contaminants. Am J Physiol Regul Integr Comp Physiol 2005; 289:R348–52Steiner, AA Chakravarty, S Robbins, JR Dragic, AS Pan, J Herkenham, M Romanovsky, AA
Steiner AA, Ivanov AI, Serrats J, Hosokawa H, Phayre AN, Robbins JR, Roberts JL, Kobayashi S, Matsumura K, Sawchenko PE, Romanovsky AA: Cellular and molecular bases of the initiation of fever. PLoS Biol 2006; 4:e284Steiner, AA Ivanov, AI Serrats, J Hosokawa, H Phayre, AN Robbins, JR Roberts, JL Kobayashi, S Matsumura, K Sawchenko, PE Romanovsky, AA
Marshall JC, Innes M: Intensive care unit management of intra-abdominal infection. Crit Care Med 2003; 31:2228–37Marshall, JC Innes, M
Mollen KP, Anand RJ, Tsung A, Prince JM, Levy RM, Billiar TR: Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006; 26:430–7Mollen, KP Anand, RJ Tsung, A Prince, JM Levy, RM Billiar, TR
Vaneker M, Joosten LA, Heunks LM, Snijdelaar DG, Halbertsma FJ, van Egmond J, Netea MG, van der Hoeven JG, Scheffer GJ: Low-tidal-volume mechanical ventilation induces a toll-like receptor 4-dependent inflammatory response in healthy mice. Anesthesiology 2008; 109:465–72Vaneker, M Joosten, LA Heunks, LM Snijdelaar, DG Halbertsma, FJ van Egmond, J Netea, MG van der Hoeven, JG Scheffer, GJ
Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, Demeyer I, Sainati S, Amlot N, Cao C, Ii M, Matsuda H, Mouri K, Cohen J: A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010; 38:1685–94Rice, TW Wheeler, AP Bernard, GR Vincent, JL Angus, DC Aikawa, N Demeyer, I Sainati, S Amlot, N Cao, C Ii, M Matsuda, H Mouri, K Cohen, J
Fig. 1.  Changes in mean arterial blood pressure (A  ), cardiac index (B  ), heart rate (C  ), and body temperature (D  ) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure (MAP) at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P  ≤ 0.05. *, a significant difference between TAK-242 and vehicle; and †, a significant difference between vehicle and NE.
Fig. 1. 
	Changes in mean arterial blood pressure (A 
	), cardiac index (B 
	), heart rate (C 
	), and body temperature (D 
	) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure (MAP) at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P 
	≤ 0.05. *, a significant difference between TAK-242 and vehicle; and †, a significant difference between vehicle and NE.
Fig. 1.  Changes in mean arterial blood pressure (A  ), cardiac index (B  ), heart rate (C  ), and body temperature (D  ) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure (MAP) at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P  ≤ 0.05. *, a significant difference between TAK-242 and vehicle; and †, a significant difference between vehicle and NE.
×
Fig. 2.  Changes in urine output (A  ), creatinine clearance (B  ), plasma (P) creatinine (C  ), blood urea nitrogen (BUN) (D  ), P-lactate (E  ), and urinary N  -acetyl-β-d-glucosaminidase (U-NAG) (F  ) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P  ≤ 0.05. * indicates a significant difference between TAK-242 and vehicle; and #,  a significant difference between TAK-242 and NE.
Fig. 2. 
	Changes in urine output (A 
	), creatinine clearance (B 
	), plasma (P) creatinine (C 
	), blood urea nitrogen (BUN) (D 
	), P-lactate (E 
	), and urinary N 
	-acetyl-β-d-glucosaminidase (U-NAG) (F 
	) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P 
	≤ 0.05. * indicates a significant difference between TAK-242 and vehicle; and #, 
	a significant difference between TAK-242 and NE.
Fig. 2.  Changes in urine output (A  ), creatinine clearance (B  ), plasma (P) creatinine (C  ), blood urea nitrogen (BUN) (D  ), P-lactate (E  ), and urinary N  -acetyl-β-d-glucosaminidase (U-NAG) (F  ) in response to lipopolysaccharide infusion and treatment with the selective toll-like receptor 4 antagonist, TAK-242 (6 mg/24 h, n = 7), vehicle (n = 7), or norepinephrine (NE, n = 6), titrated to maintain mean arterial pressure at baseline levels. Data are expressed as mean ± SEM. Differences between treatments were evaluated by ANOVA using time points 0, 12, and 24 h after commencement of lipopolysaccharide infusion and were considered significant at P  ≤ 0.05. * indicates a significant difference between TAK-242 and vehicle; and #,  a significant difference between TAK-242 and NE.
×
Table 1.  Systemic Variables
Image not available
Table 1.  Systemic Variables
×